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Abstract
Purpose—Several studies have shown substantially longer survival among persons with Down 
syndrome in recent decades. We examined survival patterns among Danish persons with Down 
syndrome by karyotype.
Methods—A national cohort of 3,530 persons with Down syndrome identified from the Danish 
Cytogenetic Register and a reference cohort of persons without Down syndrome randomly 
selected from the general population were followed from 1 April 1968 to 15 January 2009 by 
linkages to the Register of Causes of Death and the Civil Registration System.
Results—Overall, persons with Down syndrome had higher mortality than the reference cohort 
but to a lesser degree for persons with mosaic trisomy 21 than for persons with standard trisomy 
21 or with Robertsonian translocations (hazard ratio 4.98 (95% confidence interval 3.51–7.08), 
8.94 (8.32–9.60), and 10.23 (7.50–13.97), respectively). Among persons with Down syndrome 
born after April 1968, more recent birth cohorts had lower mortality rates than older birth cohorts, 
which was largely due to declining mortality among persons with Down syndrome who also had 
congenital heart defects.
Conclusion—Recent birth cohorts of persons with Down syndrome experienced declining 
mortality, likely due to treatment for congenital heart defects, and persons with mosaic trisomy 21 
had better survival than persons with other Down syndrome karyotypes.
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Down syndrome (DS) is the most common identifiable genetic cause of intellectual 
disability, occurring in ~1 in 700 births, although the prevalence at birth varies depending on 
the maternal age structure and utilization of prenatal screening and pregnancy termination in 
the population studied.1–3 In most cases (90–95%), DS is caused by an extra free 
chromosome 21 (standard trisomy 21), which usually results from nondisjunction during 
maternal meiosis. Other cytogenetic alterations that may produce DS include Robertsonian 
translocations (a centric fusion between two acrocentric chromosomes, most commonly 
chromosomes 14 and 21) and mosaic trisomy 21 (in which only a portion of cells have an 
extra chromosome 21), each occurring in 2–4% of DS cases.4,5 The phenotypic 
manifestations associated with mosaic trisomy 21 are similar to those of standard trisomy 
21, although the phenotype tends to be milder.6 Some studies have suggested that children 
with mosaic trisomy 21 appear to have better intellectual development than those with 
standard trisomy 21.7,8
Several studies have shown substantially longer survival for persons with DS in recent 
decades,9–13 but in nearly all those studies, survival by DS karyotype was not examined. 
One recent study suggested that children with mosaic DS have better survival than those 
with standard trisomy 21.14 This finding was based on a small number of persons with 
mosaic DS from one metropolitan area in the United States. Because survival for children 
with congenital heart defects has improved in recent decades,15 the question arises as to 
what extent the recent improvement in survival for persons with DS reflects changes in the 
karyotypic composition of persons with DS or in improvements in survival for persons with 
DS and congenital heart defects. In addition, most of the previous studies did not include a 
comparison with survival in the general population. In this analysis, we used a Danish 
population-based follow-up study to examine survival among individuals with different DS 
karyotypes, as compared with that in the general population, as well as survival of persons 
with DS and congenital heart defects.
Materials and Methods
Study design
We identified a cohort of persons with DS using the Danish Cytogenetic Register, which 
includes information on persons with DS diagnosed in Denmark since 1961. Then a cohort 
of persons without DS was randomly selected from the general population, matched on birth 
year with the persons with DS in a 1:20 ratio of DS cases to noncases, using the Civil 
Registration System. The two cohorts were linked to a number of nationwide registers, 
including the Register of Causes of Death, the Medical Birth Register, and the National 
Hospital Register. Data linkages were based on the personal identification number, which 
was introduced in Denmark in April 1968, and is assigned to each resident. The personal 
identification number, which includes date of birth and a code for sex, is unique to each 
resident, allowing complete follow-up and linkage to all national civil registers, including 
data on death, migration, and hospitalization. This study was approved by the Danish Data 
Protection Agency.
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Identification of persons with DS
The Danish Cytogenetic Register was founded in 1968 to collect information on 
constitutional chromosomal abnormalities in Denmark. The register is based on reports from 
cytogenetic laboratories throughout the country and provides virtually complete coverage of 
constitutional chromosomal abnormalities diagnosed in Denmark.16 The register also 
retrospectively collected data on all analyses performed since the introduction of the 
cytogenetic analysis in 1961.17 By December 2007, the Cytogenetic Register contained 
information on 3,551 individuals with a postnatal cytogenetic diagnosis of DS, a verified 
personal identification number (i.e., alive on 1 April 1968 or born later), and residence in 
Denmark at the time of the cytogenetic study.
A karyotype based on studies of peripheral blood is available for all persons with DS in this 
study. Cytogenetic studies reported as trisomy G in the 1960s and 1970s (before the routine 
use of banded karyotyping that permitted distinguishing the two G-group chromosomes) 
were accepted as trisomy 21. Persons who were studied with fluorescence in situ 
hybridization only were not included. All reported karyotypes were reviewed (by S.A.R., 
J.M.F., and H.H.) and additional data from the reporting cytogenetic laboratory were 
requested when indicated. After the review, five persons were reclassified as not having 
trisomy 21. Individuals with trisomy 21 and an additional cytogenetic aberration were 
excluded: XYY (n = 1), XXY (n = 2), XXX (n = 3), translocations (n = 7), inversions (n = 
2), and deletion (n = 1). The final cohort consisted of 3,530 individuals (1,928 males and 
1,602 females; birth years: 1878–2007). Of these persons, 1,266 (35.9%) were born before 
April 1968.
Sampling of reference cohort
Based on the initial cohort of persons with DS (n = 3,551), 71,020 persons without DS were 
randomly selected from the Civil Registration System,18 with a sampling frame of 20:1 and 
matching on birth year. With the subsequent exclusion of 21 cases from the initial DS cohort 
(see above), 420 matched referents were dropped, resulting in 70,600 individuals available 
for comparison in the reference cohort.
Data on death
Information on death was obtained by linkage to the Register of Causes of Death and the 
Civil Registration System.18,19 Up to three causes of death were recorded for each 
individual in the Register of Causes of Death, based on the 8th Revision of International 
Classification of Diseases (ICD8) from 1969 to 1993 or the 10th Revision of International 
Classification of Diseases (ICD10) since 1994. We used data on the primary cause of death, 
and in a few cases where “Down syndrome” was coded as the primary cause of death, we 
used data from the secondary cause of death. Data from the Register of Causes of Death 
were available between 1 January 1970 and 31 December 2006, and data on vital status and 
migration from the Civil Registration System were available between 1 April 1968 and 15 
January 2009. In this study, we used available information on death over the period from 1 
April 1968 to 15 January 2009, from the two sources. In cases of inconsistency between the 
two registers, we used information from the Civil Registration System.
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We included sex (female, male), birth cohort (before April 1968, 1968–1979, 1980–1989, 
1990–1999, and 2000–2007), birth weight (≥2,500 and <2,500 g), congenital heart defects 
(ICD8: 746–747.4; ICD10: Q20–Q26) (yes, no), and gastrointestinal tract defects (ICD8: 
750–751; ICD10: Q38–Q45) (yes, no) as covariates. The available information on these 
covariates was dependent on when the registers were established. Information on sex and 
birth year was available for all cohort members. Information on birth weight was obtained 
from the Medical Birth Register and was available for those born after 1973. Information on 
congenital malformations was obtained from the National Hospital Register and was 
available for those born after 1977.
Statistical analysis
We estimated survival probabilities for persons with each of the three DS karyotypes as well 
as for the reference cohort using the Kaplan–Meier product-limit method. We used Cox 
proportional hazards regression models to estimate mortality hazard rate ratios for the cohort 
of persons with DS and for the reference cohort. Cohort members born after 1 April 1968 
were followed from birth until time of death, emigration, or the end of follow-up (15 
January 2009), whichever came first. For persons born before April 1968, follow-up was 
left-truncated, starting on 1 April 1968. The Cox regression models were stratified on birth 
year.
We examined associations of the covariates with mortality by restricting the Cox regression 
models to the cohort of persons with DS after stratification into mosaic and nonmosaic 
groups (the latter included standard trisomy 21 and Robertsonian translocation DS). The 
analyses on birth weight, congenital heart defects, and gastrointestinal tract defects were 
restricted to various birth periods defined by the availability of the information on these 
variables. We further checked for effect measure modification on mortality between 
congenital heart defects and birth cohort by including an interaction term in the regression 
model. Last, we examined causes of death in relation to karyotype and age at death (<20 and 
≥20 years).
Results
Karyotype and congenital heart defects
Of 3,530 persons with DS, 3,272 (92.7%) individuals were classified as standard trisomy 21, 
144 (4.1%) as DS resulting from a Robertsonian translocation, and 114 (3.2%) as mosaic 
trisomy 21. The median percentage of trisomy 21 cells in persons with mosaic DS was 60% 
(range: 2–95%), but this information was available in only 24 of 114 persons with mosaic 
DS. The karyotypic composition of persons with DS did not change over the study period 
(Table 1).
About 50% of persons with standard trisomy 21 and Robertsonian translocation DS had 
congenital heart defects, whereas about 25% of persons with mosaic DS had congenital 
heart defects. Younger cohorts of persons with standard trisomy 21 were more likely to have 
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a diagnosis of congenital heart defects, and a similar tendency was also seen for younger 
cohorts of persons with Robertsonian translocation DS and mosaic DS (Table 1).
Survival
Overall, 1,073 persons with DS died between 1 April 1968 and 15 January 2009 (1,000 
deaths for standard trisomy 21, 41 for Robertsonian translocation DS, and 32 for mosaic 
DS). The estimated 1- and 50-year survival probabilities were 0.89 (95% confidence interval 
0.87–0.90) and 0.64 (0.62–0.67), respectively, for persons with standard trisomy 21, 0.91 
(0.83–0.96) and 0.66 (0.53–0.75), respectively, for persons with Robertsonian translocation 
DS, 0.94 (0.86–0.98) and 0.81 (0.67–0.90), respectively, for persons with mosaic DS, 
whereas the corresponding estimates were 0.99 (0.99–0.99) and 0.94 (0.94–0.95), 
respectively, for the reference cohort (Figure 1).
Hazard ratio of mortality
Persons with DS had a higher mortality rate than the reference population; adjusted hazard 
ratio was 8.94 (8.32–9.60) for persons with standard trisomy 21, 10.23 (7.50–13.97) for 
persons with Robertsonian translocation DS, and 4.98 (3.51–7.08) for persons with mosaic 
DS. Restricting the analyses to persons who were entered into the cohort at birth (i.e., those 
born after 1 April 1968) increased these estimates (Table 2). Among those born after 1 April 
1968, no significant effect measure modifications were detected between DS or reference 
group and birth year (P = 0.08 for standard trisomy 21, P = 0.12 for Robertsonian 
translocation DS, and P = 0.53 for mosaic DS), indicating a rather similar decline in 
mortality for both persons with DS and the general population in recent decades.
Analyses of mortality by covariates
Analyses of mortality among persons with DS by covariate strata are shown in Table 3. 
Among persons with nonmosaic DS karyotypes, mortality declined from earlier to more 
recent birth cohorts, and those who were of low birth weight or who had congenital heart 
defects or gastrointestinal tract defects had higher mortality rates than those without the birth 
characteristic. Similar tendencies were seen for persons with mosaic DS, although the 
numbers were sparse. No significant difference in mortality was seen between males and 
females with DS.
The decline in mortality rates among persons with nonmosaic DS occurred only in persons 
with congenital heart defects (a significant effect measure modification on mortality was 
observed between congenital heart defects and birth year, P < 0.001) (Supplementary Table 
S1 online). Mortality in the first year of life revealed a similar trend (data not shown).
Causes of death
Causes of death were available for 983 persons with DS, with about one-third dying from 
congenital heart defects (Supplementary Table S2 online). The proportion of deaths due to 
congenital heart defects was greater among persons with standard trisomy 21 and 
Robertsonian translocation DS than among persons with mosaic DS, whereas the opposite 
was true for deaths due to neoplasm and diseases of the circulatory system.
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Congenital heart defects were the main cause of death among persons with DS who died 
before the age of 20 years, whereas deaths due to diseases of the respiratory systems and the 
circulatory system were the main reasons among persons with DS who died after the age of 
20 years.
Discussion
In this national cohort of persons with DS who were followed over a 40-year period, we 
observed that persons with DS had a higher mortality than the general population, with 
better survival for persons with mosaic DS than for persons with standard trisomy 21 or 
Robertsonian translocation DS. In accordance with the general population, more recent birth 
cohorts had lower mortality rates than earlier birth cohorts. The decline in mortality was in 
particular seen for persons with DS who were born with congenital heart defects. We 
observed no changes in the DS karyotypic composition over the study period, which has not 
been reported before.
Previous studies reported that persons with DS had a mortality of 5–11 times that of the 
general population,9,11,20,21 and our estimates support this. Many previous studies lacked 
information on mortality early in life, as our study does for those born before 1968. This 
biases the relative risk estimates toward lower values, because death in infancy is 
disproportionately more frequent among people with DS.22 As expected, restricting the 
analysis in our study to the cohort that was followed from birth increased the relative 
mortality rates (Table 1). Persons with Robertsonian translocation DS had a survival pattern 
similar to persons with standard trisomy 21, which is expected. Due to small sample size, its 
survival curve fluctuated around that of standard trisomy 21 (Figure 1). Persons with mosaic 
DS would be expected to have a lower mortality than those with other DS karyotypes, 
because these people tend to have milder phenotypic manifestations,6 and our data support 
this and are consistent with the findings in a previous study.14
Most previous studies,9,13,20,23–26 although not all,27 observed no statistically significant 
differences in mortality between males and females with DS. We found a 6% higher 
mortality in males but with confidence intervals that included no difference. Persons with 
DS who were of low birth weight or who had congenital heart or gastrointestinal tract 
defects had higher mortality.9,12,26 One of our novel findings is that all of the decline in DS 
mortality rate found in our study appears to have occurred among persons with congenital 
heart defects, and this indicates an effect of treatment for this group. We also found that 
persons with DS who died before the age of 20 years were most likely to have died from 
congenital heart defects. More recent cohorts of persons with DS were more likely to have a 
diagnosis of congenital heart defects, probably indicating more complete diagnoses of 
congenital heart defects (early in life) rather than increased prevalence.15 As we had limited 
information on the severity of the defects, we could not exclude the possibility that the 
improvement in survival of children with congenital heart defects might reflect the 
possibility that live births with DS in recent birth cohorts may exclude cases with more 
severe forms of congenital heart defects that were prenatally diagnosed and resulted in 
subsequent pregnancy terminations.3
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The elderly persons with DS in our study were all individuals with DS who entered the 
cohort in April 1968. Cytogenetic diagnostics became available in the early 1960s, and our 
data included only persons with DS with cytogenetic verification. It is possible that elderly 
persons with DS who were functioning well in 1968 would not have been candidates for 
laboratory testing until they came into contact with the health-care system for other reasons. 
If so, we may also have oversampled elderly persons with DS with health problems who 
might have higher mortality at relatively younger ages as compared with elderly persons 
with DS who did not get karyotyped.
We believe that all persons with DS born after 1968 are very likely to have been diagnosed 
cytogenetically, and most of them were diagnosed within the first days of life. We started 
observation at the time of birth, not at the time of diagnosis, because we believe that all 
those who died early in life would be diagnosed if they had DS and the actual time of 
diagnosis might be influenced by comorbidities. To substantiate this assumption, we 
repeated all analyses by comparing children from the age of 1 and found similar results as 
those presented. We also found similar results when starting observation at the time of 
diagnosis rather than at the time of birth for those born after April 1968.
Our study had a number of strengths. We identified a large number of persons with DS from 
Denmark from the Danish Cytogenetic Register, and these persons were classified into 
groups with different karyotypes based on the results of cytogenetic testing. These persons 
were followed for up to 40 years, and we had virtually complete follow-up for all persons 
with DS in the country, due to the high-quality population-based registers on mortality and 
migration.
The Danish Cytogenetic Register provides a unique opportunity to study persons with a 
specific chromosome abnormality, such as DS, Klinefelter syndrome, Turner syndrome, and 
several other cytogenetic conditions.16,28 By linking a cohort of persons with a specific 
chromosome abnormality to other national registers, it is possible to investigate mortality 
and comorbidities, including cancer risk, among persons with these chromosome 
abnormalities.29–31 In addition, this approach can allow identification of new genetic regions 
that might contribute to the risk for other conditions, such as autism and schizophrenia.32,33
Results show a declining mortality rate for persons with DS over time that probably resulted 
from improvement in the treatment of heart malformations. It is important to understand the 
factors, including comorbidities, that affect survival among persons with DS. In addition, 
these data suggest that there is a need to study the role of healthcare and other social services 
needed for persons with DS as they age.
Supplementary Material
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Figure 1. Kaplan–meier survival curves for three karyotypes of persons with down syndrome 
and reference cohort, denmark, 1968–2009
(Number of persons and deaths: 3,272 and 1,000, respectively, for persons with standard 
trisomy 21, 144 and 41, respectively, for persons with Robertsonian translocations, 114 and 
32, respectively, for persons with mosaic trisomy 21, and 70,590 and 4,683, respectively, for 
the reference cohort)
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